Canagliflozin benefits cohort of type 1 diabetes patients

NEW ORLEANS – Compared with placebo, canagliflozin improved glycemic control and reduced glycemic variability over 18 weeks in adults with type 1 diabetes that had been inadequately controlled with...
Source: Clinical Endocrinology News - Category: Endocrinology Source Type: news